Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Dow
Medtronic
Boehringer Ingelheim
McKinsey

Last Updated: February 1, 2023

CLINICAL TRIALS PROFILE FOR LISINOPRIL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Lisinopril

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000542 ↗ Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1993-08-01 To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.
NCT00004266 ↗ Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes Completed Hennepin County Medical Center, Minneapolis Phase 3 1993-08-01 OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.
NCT00004266 ↗ Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 1993-08-01 OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lisinopril

Condition Name

Condition Name for Lisinopril
Intervention Trials
Hypertension 45
Cardiovascular Disease 6
Healthy 6
Diabetic Nephropathy 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lisinopril
Intervention Trials
Hypertension 49
Kidney Diseases 17
Cardiovascular Diseases 10
Diabetes Mellitus 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lisinopril

Trials by Country

Trials by Country for Lisinopril
Location Trials
United States 434
Canada 8
Puerto Rico 6
Spain 6
Italy 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lisinopril
Location Trials
Texas 23
Ohio 21
California 21
New York 19
Minnesota 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lisinopril

Clinical Trial Phase

Clinical Trial Phase for Lisinopril
Clinical Trial Phase Trials
Phase 4 31
Phase 3 24
Phase 2/Phase 3 2
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lisinopril
Clinical Trial Phase Trials
Completed 82
Recruiting 12
Terminated 12
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lisinopril

Sponsor Name

Sponsor Name for Lisinopril
Sponsor Trials
GlaxoSmithKline 14
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 9
Novartis 7
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lisinopril
Sponsor Trials
Other 130
Industry 63
NIH 22
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
AstraZeneca
Dow
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.